A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs

Journal of Bone and Joint Surgery

Volumn 90, Issue 6, 2008, Pages 1197-1205

  Sander, Beate ^a   Elliot Gibson, Victoria ^b   Beaton, Dorcas E ^b   Bogoch, Earl R ^b   Maetzel, Andreas ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ADULT; AGE; AGED; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HIP FRACTURE; HOSPITAL COST; HUMAN; INCIDENCE; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT REFERRAL; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 44649195746     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.G.00980     Document Type: Article

References (29)

1. Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM; Fracture Intervention Trial Research Group. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int. 2001;12:654-60.
2. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003;14:722-7.
3. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-52.
4. Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003;21:305-14.
5. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med. 2003;19:395-414.
6. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767-78.
7. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35:293-305.
8. Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM. Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am. 2006;88:25-34.
9. Chevalley T, Hoffmeyer P, Bonjour JP, Rizzoli R. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int. 2002;13:450-5.
10. Harrington JT, Barash HL, Day S, Lease J. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum. 2005;53:198-204.
11. Majumdar SR, Johnson JA, Lier DA, Russell AS, Hanley DA, Blitz S, Steiner IP, Maksymowych WP, Morrish DW, Holroyd BR, Rowe BH. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int. 2007;18:261-70.
12. McLellan AR, Gallacher SJ, Fraser M, McQuillian C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int. 2003;14:1028-34.
13. Bogoch ER, Elliot-Gibson V, Beaton DE, Baburam A, Jamal SA, Josse RG, Murray TM. Adherence with osteoporosis assessment and treatment after fragility fracture in an inner city orthopaedic unit [abstract]. J Bone Miner Res. 2006;21 Suppl 1:S421.
14. Streeten EA, Mohamed A, Gandhi A, Orwig D, Sack P, Sterling R, Pellegrini VD Jr. The inpatient consultation approach to osteoporosis treatment in patients with a fracture: is automatic consultation needed? J Bone Joint Surg Am. 2006;88:1968-74.
15. Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int. 2001;12:271-8.
16. Robinson CM, Royds M, Abraham A, McQueen MM, Court-Brown CM, Christie J. Refractures in patients at least forty-five years old. A prospective analysis of twenty-two thousand and sixty patients. J Bone Joint Surg Am. 2002;84:1528-33.
17. Singer BR, McLauchlan GJ, Robinson CM, Christie J. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br. 1998;80:243-8.
18. Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:16-23.
19. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-8.
20. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ. 2000;163:819-22.
21. Hawker G, Ridout R, Ricupero M, Jaglal S, Bogoch E. The impact of a simple fracture clinic intervention in improving the diagnosis and treatment of osteoporosis in fragility fracture patients. Osteoporos Int. 2003;14:171-8.
22. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003-8.
23. Hunink M, Glasziou PP, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein M. Decision making in health and medicine: integrating evidence and values. Cambridge, UK: Cambridge University Press; 2001.
24. Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003;14:146-51.
25. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997;103:12S-19S.
26. Fierens J, Broos PL. Quality of life after hip fracture surgery in the elderly. Acta Chir Belg. 2006;106:393-6.
27. van Balen R, Steyerberg EW, Polder JJ, Ribbers TL, Habbema JD, Cools HJ. Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthop Relat Res. 2001;390:232-43.
28. Willig R, Keinänen-Kiukaaniemi S, Jalovaara P. Mortality and quality of life after trochanteric hip fracture. Public Health. 2001;115:323-7.
29. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22.